Movement disorder experts Jonathan Isaacson, MD, and Abhishek Lenka, MD, PhD, discuss early identification and accurate diagnosis of autonomic dysfunction in Parkinson disease, highlighting emerging biomarkers and monitoring tools that may enable more personalized care.
At ATMRD 2026, a neurologist at UCLA discussed the growing recognition of demoralization in Parkinson disease, highlighting how it differs from depression and apathy and outlining strategies to help patients maintain resilience, purpose, and quality of life. [Watch time: 5 minutes]
AT ATMRD 2026, the CEO and founder of Yes, and... X discussed why social connection and support groups should be viewed as critical components of Parkinson disease care, alongside traditional medical management. [WATCH TIME: 3 minutes]
The professor of psychiatry and neurology reviewed approaches to treating chorea, cognitive impairment, apathy, irritability, and aggression in Huntington disease, while highlighting the promise of huntingtin-lowering therapies.
At ATMRD 2026, the director of the Parkinson's Disease and Movement Disorders Program at the Cleveland Clinic discussed the importance of movement phenomenology and accurate diagnosis in guiding treatment decisions for patients with hyperkinetic disorders. [WATCH TIME: 7 minutes]
At ATMRD 2026, the professor of neurology at Georgetown University Medical Center discussed how clinicians can distinguish Alzheimer disease from Lewy body dementia. [WATCH TIME: 5 minutes]
Characterization of early-start TRAILBLAZER-ALZ 2 participants who required continued donanemab in the long-term extension suggests durable clinical benefit with fewer cumulative doses.
The professor at MedStar Georgetown University Hospital spoke about a live session that featured patient evaluations and injection demonstrations designed to help clinicians refine treatment strategies for dystonia, spasticity, sialorrhea, and other neurologic conditions. [WATCH TIME: 2 minutes]
Early data from the Clinical Nurse Navigator program show that more than 99% of patients with Parkinson's disease reaching a first optimization dose of continuous subcutaneous apomorphine infusion did so without antiemetic pretreatment.
At ATMRD 2026, the director of Movement Disorders at Banner Sun Health Research Institute discussed emerging biomarker and imaging technologies, the importance of clinical diagnostic expertise, and the evolving treatment landscape for atypical parkinsonian disorders and adult-onset ataxias.
Real-world survey data suggest deutetrabenazine treatment may be associated with improvements in patient- and caregiver-reported quality-of-life outcomes among individuals with Huntington disease chorea.
The CEO and founder of Yes, And...eXercise (YAX) discussed how support groups, psychosocial connection, and hybrid telehealth models can complement pharmacologic treatment in Parkinson disease. [WATCH TIME: 3 minutes]
Exploratory post hoc data suggest prompt pimavanserin initiation within 6 to 12 months of PDP onset may yield a more favorable symptom trajectory, though prospective confirmation is needed.
The CEO and cofounder of LSVT Global talked about how evidence-based therapies like LSVT LOUD and LSVT BIG can improve speech and movement in patients with Parkinson disease. [WATCH TIME: 5 minutes]
The physician assistant specializing in Parkinson disease talked about the shared decision-making process when discussing advanced therapies for movement disorder care with patients. [WATCH TIME: 3 minutes]
The nurse practitioner in the Center for Movement Disorders & Neurorestoration at the University of Florida discussed clinical experiences with deep brain stimulation for atypical MS tremor and PD. [WATCH TIME: 5 minutes]
The director of the Movement Disorders Clinic at Houston Methodist Hospital outlined a stepwise approach for identifying, managing, and treating hallucinations in patients with Parkinson disease. [WATCH TIME: 3 minutes]
Experts shared their clinical perspectives on trending topics in the treatment and management of movement disorders at the 4th Annual Advanced Therapeutics in Movement and Related Disorders (ATMRD) Congress.
At the 2025 ATMRD Congress, a patient advocate living with Parkinson disease emphasized the importance of amplifying patient voices at educational conferences for movement disorders. [WATCH TIME: 5 minutes]
The physician assistant specializing in Parkinson disease talked about how comorbidities and patient preference guide clinical decisions in prescribing on-demand therapies for Parkinson disease. [WATCH TIME: 5 minutes]
The CEO and cofounder of LSVT Global highlighted the importance of clinicians referring their patients with Parkinson disease early to evidence-based physical therapies, occupational therapies, and speech therapies. [WATCH TIME: 5 minutes]
At the 2025 ATMRD Congress, Anissa Mitchell, LCSW, chief program officer at PMD Alliance, discussed immersive, patient-focused sessions aimed at improving clinicians’ empathy, communication, and understanding of Parkinson disease and related disorders.
The medical director of CNS clinical cevelopment at AskBio discussed long-term data presented at ATMRD from the company’s phase 1b trial assessing the investigational gene therapy AB-1005 in Parkinson disease. [WATCH TIME: 6 minutes]
The advisory board member of the Parkinson's Foundation shared personal insights on how love, present-moment awareness, and hope shaped her approach to living with the Parkinson disease. [WATCH TIME: 6 minutes]
The chief program officer at PMD Alliance described an interactive program designed to help health care providers better understand the lived experience of patients with Parkinson disease and related movement disorders. [WATCH TIME: 6 minutes]
A duo of experts discussed a novel hybrid trial approach combining in-home video assessments with traditional visits to improve Parkinson disease research participation and assess a new investigational therapy. [WATCH TIME: 7 minutes]
The movement disorder specialist and patient living with Parkinson disease highlighted the need for a more human-centered approach in managing chronic and progressive movement disorders. [WATCH TIME: 6 minutes]
The neuropsychiatry researcher at King's College London highlighted significant gender differences in anxiety, depression, quality of life, and social support among patients with PD undergoing deep brain stimulation. [WATCH TIME: 5 minutes]
The assistant professor of medicine at Stanford University highlighted how gastrointestinal dysfunction in Parkinson disease can affect levodopa bioavailability and symptom management. [WATCH TIME: 7 minutes]
The director of movement disorders at the Banner Sun Health Research Institute discussed distinguishing atypical Parkinsonian disorders early and planning care around their complex symptomatology. [WATCH TIME: 4 minutes]
